PRESS RELEASE published on 02/09/2024 at 14:36, 9 months 11 days ago Form 8.3 - The Vanguard Group, Inc.: Barratt Developments plc The Vanguard Group, Inc. discloses 4.86% ownership of Barratt Developments plc's relevant securities in a Form 8.3. Public disclosure includes 47,379,144 10p ordinary shares The Vanguard Group, Inc. Form 8.3 Relevant Securities Ownership Disclosure Barratt Developments Plc
PRESS RELEASE published on 02/08/2024 at 15:20, 9 months 12 days ago Form 8.3 - The Vanguard Group, Inc.: Barratt Developments plc The Vanguard Group, Inc. discloses a 4.86% interest in Barratt Developments plc. Further disclosures are made for Redrow plc. No supplemental forms attached The Vanguard Group, Inc. Disclosure Redrow Plc Barratt Developments Plc Supplemental Forms
Published on 11/21/2024 at 14:15, 10 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 25 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 25 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 25 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 9 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 10 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 50 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 27 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 5 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 40 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 40 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
